Ureter Cancer Treatment Options

• Ureter cancer treatment is highly individualized, based on the tumor’s stage and grade, its location, the health of the other kidney, and whether the cancer has come back.
• Nephroureterectomy — the surgical removal of the whole kidney together with its ureter and a rim of bladder tissue at the point where they meet — is the standard surgical treatment and the option most patients with this cancer undergo.
• For carefully selected patients, less extensive procedures such as segmental resection of the lower ureter can help preserve the kidney, though some kidney-sparing techniques remain under clinical study.
• Chemotherapy regimens used for metastatic bladder cancer, along with immunotherapy checkpoint inhibitors, are often applied to advanced or recurrent ureter cancer because the two cancers share the same cell type.
• Because evidence for treating regional or metastatic ureter cancer is still limited, clinical trial participation is frequently part of the conversation, alongside long-term follow-up care after treatment.

Understanding Ureter Cancer Treatment Choices

Deciding on the most appropriate ureter cancer treatment is worked out together with a cancer care team, weighing the specific features of the tumor against the patient’s overall health. The goal is to remove or control the cancer while preserving kidney function and quality of life whenever possible.

Factors Influencing Treatment Decisions

Several factors influence the selection of ureter cancer treatment options:

• Tumor Stage and Grade: How deeply the tumor has invaded the tissue layers of the renal pelvis or ureter, and how aggressive it looks under a microscope, are primary factors in choosing treatment.
• Location of the Tumor: Where the tumor sits within the renal pelvis or ureter affects which surgical approaches are possible.
• Health of the Other Kidney: Because the standard surgery removes an entire kidney, the function of the remaining kidney is a key consideration, especially if it is already reduced.
• Whether the Cancer Has Recurred: Treatment for cancer that comes back depends on where it recurs and what treatment was given before.

Staging and Prognosis Considerations

Staging shows the extent of the disease — how deep the tumor sits within the tissue layers of the renal pelvis or ureter, and whether it involves nearby lymph nodes or distant organs — and, together with tumor grade, is one of the main factors that shapes which treatments are considered. Encouragingly, most ureter cancer can be cured when it is found early, before it has spread beyond the ureter.

Surgical Approaches for Ureter Cancer

Surgery is the primary treatment for ureter cancer, and nephroureterectomy is considered the treatment of choice for most patients with this disease.

Nephroureterectomy Procedures

Nephroureterectomy takes out the whole affected kidney and its ureter, along with a rim of bladder tissue at the point where they join, because leftover ureter tissue carries a real risk of new tumor growth. Most people diagnosed with ureter cancer undergo this procedure.

Endoscopic and Segmental Resection

For carefully selected patients, less extensive options may help preserve kidney function:

• Segmental Resection of the Ureter: This procedure removes only the cancerous portion of the ureter and reconnects the healthy ends. This option applies only to superficial tumors confined to the lowest third of the ureter, close to where it joins the bladder.
• Kidney-Sparing, Minimally Invasive Techniques: Approaches such as fulguration (destroying tissue with an electric current), laser destruction of the tumor, or removal of a limited area of the renal pelvis are sometimes used, mainly for patients who have only one working kidney or reduced kidney function. These techniques are still considered investigational: long-term outcomes have not been well studied, and how reliably they control the cancer is not yet established.

Because of this uncertainty, patients who choose an organ-sparing approach need close, ongoing monitoring for recurrence.

Non-Surgical Ureter Cancer Treatments

Non-surgical treatments play a role mainly for cancer that has spread beyond the ureter, cancer that has returned after treatment, or patients who are not candidates for surgery.

Chemotherapy and Immunotherapy

Ureter cancer and bladder cancer arise from the same type of cell, called urothelial (transitional) cells, so chemotherapy regimens shown to work against metastatic bladder cancer are generally applied to ureter cancer that has spread or returned as well; these regimens typically combine cisplatin with other drugs.

Immunotherapy with checkpoint inhibitors — drugs that block proteins such as PD-1 or PD-L1 so the immune system can better recognize cancer cells — has activity against urothelial carcinoma and is generally used for patients who have already had platinum-based chemotherapy or who cannot tolerate it.

Radiation Therapy Options

Radiation therapy uses high-energy beams to damage cancer cells. For ureter cancer that has spread regionally, to tissue around the kidney or to nearby lymph nodes, current evidence does not show a clear benefit from either radiation therapy or systemic chemotherapy, so patients with this extent of disease are generally encouraged to discuss clinical trial options with their care team.

Beyond ureter cancer specifically, radiation is often used more broadly in oncology as a supportive tool: it can shrink tumors enough to relieve discomfort, and it is a common option for easing pain caused by cancer that has reached bone tissue.

Latest Advancements in Ureter Cancer Treatment

Research into ureter cancer continues to evolve, particularly for disease that is advanced, has spread, or has not responded to standard treatment.

Targeted Therapies and Precision Medicine

Targeted therapies are drugs designed to interfere with specific proteins that drive how cancer cells grow and divide, and they form the basis of precision medicine, in which a tumor’s genetic makeup helps guide treatment choice. For ureter cancer, testing for variants in the FGFR gene is particularly relevant: these variants occur in roughly a third of urothelial carcinomas of the ureter and renal pelvis, notably more often than in bladder tumors. The FDA has approved an FGFR-targeted drug for people with urothelial carcinoma whose tumor carries one of these variants and whose disease has progressed after chemotherapy.

Clinical Trials and Emerging Options

Because ureter cancer is uncommon and standard treatment options for regional and metastatic disease remain limited, clinical trials are an important pathway to new and improved treatments and are often discussed with patients whose disease extends beyond the ureter. Trials test new drugs, drug combinations, and surgical or radiation techniques under close medical supervision; taking part can give patients access to newer approaches while contributing to future care.

Life After Ureter Cancer Treatment

Completing active ureter cancer treatment marks the start of a period focused on recovery and ongoing monitoring.

Follow-up Care and Surveillance

After treatment, some of the same tests used for diagnosis and staging are repeated periodically to check whether the cancer has come back. Because ureter cancer shares its cell type with bladder cancer, people treated for it also have a meaningfully higher chance of later developing a bladder tumor, so ongoing cystoscopy (a scope exam of the bladder) and monitoring of the remaining kidney and ureter are part of long-term follow-up.

Managing Side Effects and Quality of Life

Treatment can affect quality of life in ways that range from physical recovery after surgery to emotional adjustment to the diagnosis. Working closely with the care team — who can address symptoms, coordinate rehabilitation, and connect patients with nutritional or psychological support as needed — is central to managing these effects well after treatment.

Frequently Asked Questions

What are the primary factors determining ureter cancer treatment?

Treatment choice is shaped mainly by the tumor’s stage and grade, its location within the renal pelvis or ureter, how well the other kidney is functioning, and whether the cancer is new or has recurred. These factors, discussed with the cancer care team, help determine whether surgery, a kidney-sparing approach, or a systemic treatment is most appropriate.

Is surgery always necessary for ureter cancer?

Nephroureterectomy is the standard treatment for localized ureter cancer and is what most patients undergo. In select cases with a small, superficial tumor in the lower ureter, a less extensive segmental resection may be an option. Once the disease has spread more widely, surgery is generally not the main approach, and those situations are more often addressed through chemotherapy, immunotherapy, or a clinical trial.

What are the newest developments in ureter cancer treatment?

Genetic testing of the tumor for FGFR gene variants, which occur relatively often in ureter and renal pelvis cancers, can identify candidates for an FDA-approved targeted therapy. Immunotherapy checkpoint inhibitors developed for urothelial cancer are also being used in advanced disease. Because much of the evidence in this area is still developing, clinical trials remain an important way patients can access newer treatment approaches.

Sources

• National Cancer Institute – Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, 2025
• National Cancer Institute – Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version, 2024
• National Cancer Institute – Bladder Cancer Treatment (PDQ®)–Health Professional Version, 2025
• National Cancer Institute – Radiation Therapy to Treat Cancer, 2025